华法林个体化用药影响因素的研究进展
CSTR:
作者:
作者单位:

(1. 大连医科大学第一临床学院,辽宁 大连 116000;2. 苏北人民医院心血管内科,江苏 扬州 225001)

作者简介:

通讯作者:

中图分类号:

基金项目:

江苏省科技厅重大临床专项(BL2013022)


Research progress in influencing factors for warfarin individualized medication
Author:
Affiliation:

(1. First Clinical College, Dalian Medical University, Dalian 116000, Liaoning Province, China;2. Department of Cardiology, Northern Jiangsu People′s Hospital, Yangzhou 225001, Jiangsu Province, China)

Fund Project:

This work was supported by the Major Clinical Projects of Department of Science and Technology of Jiangsu Province (BL2013022).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    华法林等维生素K拮抗剂是目前临床上应用最广泛的抗凝药物,主要用于预防心脏瓣膜置换、心房颤动等疾病血栓事件的发生。但影响其临床疗效的因素较多,不同个体的华法林有效剂量差异较大。随着对华法林的药物基因组学的深入研究,华法林个体化用药逐渐成为可能,但目前基因指导华法林用药的有效性仍存在争议。本文拟对影响华法林剂量的非遗传因素和遗传因素进行综述,旨为实现华法林临床精准治疗提供参考。

    Abstract:

    Warfarin, as well as other vitamin K antagonists, is the most widely used anticoagulant drug currently in clinical practice, and is mainly used to prevent thrombotic events due to heart valve replacement, atrial fibrillation and other diseases. However, there are many factors affecting its clinical efficacy, and the effective dose of warfarin varies greatly among individuals. With the in-depth study of warfarin pharmacogenomics, individualized warfarin medicine has gradually become possible. At present, the use of warfarin under genetic guidance is still controversial. This article reviewed the non-genetic factors and genetic factors that affect warfarin dose variation in order to provide a reference for disease precision treatment.

    参考文献
    相似文献
    引证文献
引用本文

单广东,顾翔.华法林个体化用药影响因素的研究进展[J].中华老年多器官疾病杂志,2021,20(7):547-551
DOI:10.11915/j. issn.1671-5403.2021.07.114

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-07-15
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-07-28
  • 出版日期:
文章二维码